Flavio Victor Signorelli
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Hospital Universitário Clementino Fraga/CCS
Unidade:
Hospital Universitário Clementino Fraga/CCS
Departamento:
Divisão Médica DMD/HU
Formação:
-
Hospital das Clínicas da Faculdade de Medicina da USP
| Pós-Doutorado | 2020 - 2022
-
Universidade Federal do Rio de Janeiro
Clinica Médica | Doutorado | 2008 - 2010
-
Universidade Federal do Rio de Janeiro
Clínica Médica | Mestrado | 1999 - 2002
-
Universidade Federal do Rio de Janeiro
| Especialização - Residencia medica | 1996 - 1999
-
Universidade Federal Fluminense
medicina | Graduação | 1989 - 1995
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:
Nenhum artigo cadastrado
Eventos:
(44.12% eventos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| COMPARISON OF SINGLE LUPUS ANTICOAGULANT POSITIVITY VERSUS TRIPLE POSITIVITY IN PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS | 10.47660/CBR.2023.2171 | 2023 |
| THE (NON-)RELEVANCE OF ANTI-CELL ANTIBODIES (ANA) IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) | 10.47660/CBR.2023.2124 | 2023 |
| DIFFERENCES BETWEEN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) PATIENTS WITH COMBINED ARTERIAL AND VENOUS EVENTS VERSUS THOSE WITH ISOLATED EVENTS | 10.47660/CBR.2023.2115 | 2023 |
| CUTANEOUS MANIFESTATIONS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) BEWARE OF LIVEDO RETICULARIS | 10.47660/CBR.2023.2110 | 2023 |
| EVALUATION OF THE QUALITY OF ANTICOAGULATION IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME TREATED WITH WARFARIN | 10.47660/CBR.2023.1969 | 2023 |
| AB0573¿REASONS FOR BREASTFEEDING AVOIDANCE: A MULTICENTER INSIGHT IN MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | 10.1136/annrheumdis-2023-eular.2271 | 2023 |
| Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up | 2022 | |
| AMAUROSIS FUGAX IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: DATA FROM APS-RIO COHORT | 10.47660/CBR.2022.1975 | 2022 |
| Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual [abstract] | 2022 | |
| IgA anticardiolipin isotype is not relevant in Brazilian primary antiphospholipid syndrome patients | 10.47660/cbr.2021.1842 | 2021 |
| Hematological manifestations in patients with antiphospholipid antibodies | 10.47660/cbr.2021.1858 | 2021 |
| Immunogenicity and safety after SARS-CoV-2 vaccine in Primary Antiphospholipid Syndrome (PAPS) | 10.47660/cbr.2021.1888 | 2021 |
| Mobile thrombi in cardiac implantable electronic device in a patient with antiphospholipid syndrome as a risk factor for the development of symptomatic pulmonary embolism: Case Report | 10.47660/cbr.2020.16873 | 2021 |
| Comparison of clinical and laboratory characteristics of patients with early vs. late onset Primary Antiphospholipid Syndrome | 10.47660/cbr.2020.16700 | 2021 |
| Avoiding misclassification of primary antiphospholipid syndrome as systemic lupus erythematosus: what are the best-performing SLE classification criteria?. | 2020 | |
| Recurrent early pregnancy loss is associated with higher aGAPSS in thrombotic Primary Antiphospholipid Syndrome. | 2019 | |
| Thrombocytopenia is highly associated with specific antiphospholipid antibodies profiles | 2019 | |
| Non-criteria manifestations, antiphospholipid profile and their associations in primary antiphospholipid syndrome (PAPS) | 2018 | |
| Arterial events in primary antiphospholipid syndrome (PAPS): Don't forget the traditional cardiovascular risk factors | 2018 | |
| THU0253¿Triple positivity to antiphospholipid antibodies in primary antiphospholipid syndrome: increased risk of arterial thromboses and abortions | 10.1136/annrheumdis-2017-eular.6774 | 2017 |
| THU0286¿Recurrence of arterial and venous thromboses in primary antiphospholipid syndrome | 10.1136/annrheumdis-2017-eular.6981 | 2017 |
| SAT0303¿Clinical differences between definite and probable antiphospholipid (APS) patients: should they be treated the same? | 10.1136/annrheumdis-2017-eular.6987 | 2017 |
| Avaliação da Monitorização da Anticoagulação de pacientes com Síndrome do Anticorpo Antifosfolipidio (SAF) e sua correlação com desfechos clínicos | 2017 | |
| Avaliação da Plaquetopenia relacionada aos Anticorpos Antifosfolipídios | 2017 | |
| Tripla positividade aos anticorpos antifosfolipídios: aumento do risco de manifestações gestacionais | 2017 | |
| Arterial Events in Primary Antiphospholipid Syndrome are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score | 2016 | |
| Anticorpos da Síndrome do Anticorpo Antifosfolipídio e suas associações clínicas: a importância da anti B2 glicoproteína | 2016 | |
| Avaliação das manifestações clínicas que não constam na classificação da Síndrome do Anticorpo Antifosfolipidio em pacientes com anticorpos persistentes | 2016 | |
| Doença cerebrovascular na Síndrome do Anticorpo Antifosfolipídio | 2016 | |
| Risk factors associated with clinical classification criteria in primary antiphospholipid syndrome: the impacte of triple positive | 2016 | |
| Thrombocytopenia in primary antiphospolipid syndrome is associated with anticardiolipin but not with other antiphospholipid antibodies | 2016 | |
| Long-term thalidomide use in refractory cutaneous lesions of lupus erythemathosus. | 2007 | |
| Ação dos Antimaláricos no Perfil Lipídico de Pacientes com Lúpus Eritematoso Sistêmico. | 2004 | |
| Prevalência de Dislipidemias e Seus Fatores de Risco em Pacientes com Lúpus Eritematoso Sistêmico | 2004 |